skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

16375

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer



Review

(5065) Total Article Views


Authors: Deshpande H, Marler V, Sosa JA

Published Date December 2011 Volume 2011:4 Pages 209 - 215
DOI: http://dx.doi.org/10.2147/OTT.S17422

Hari Deshpande1,3, Vicky Marler3, Julie Ann Sosa2,3
1
Department of Medicine, 2Department of Surgery, Yale University School of Medicine, 3Yale Cancer Center, New Haven, CT, USA

Abstract: Vandetanib (ZD6474) became the first systemic agent to be approved for the treatment of metastatic or locally advanced medullary thyroid cancer. It was a proof of principle, because it is an orally bioavailable medication that targets the growth factors felt to be important in the pathogenesis of this disease, ie, the rearranged during transfection proto-oncogene and vascular endothelial growth factor receptor. It was tested initially in two Phase II studies at doses of 100 mg and 300 mg daily. Although activity was seen at both doses, the higher dose was chosen for a randomized, placebo-controlled Phase II study. This trial, which accrued more than 300 patients, showed a statistically significant benefit for the group taking vandetanib compared with those taking placebo medication. Progression-free survival for the vandetanib arm has not been reached, compared with 19 months for the placebo arm. The main toxicity appears to be diarrhea, although some patients experienced significant side effects, including torsades de pointes and sudden cardiac death. Therefore, it is now necessary for practitioners to enroll in a Risk Evaluation Mitigation Strategy before being allowed to prescribe this medication, to reduce the risk of serious side effects occurring.

Keywords: ZD6474, medullary thyroid cancer, vandetanib



Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

 

Other articles by Dr Hari Deshpande


Readers of this article also read: